Our Technologies
Proprietary platforms. Proven science. Precision delivery.
Landmark Medicines has developed four proprietary drug delivery platforms — each engineered to address specific challenges in complex generics. From poorly soluble small molecules to biologics and long-acting therapies, our technologies convert formulation complexity into clinically and commercially viable solutions.
Soft Gel Capsules
Enhancing bioavailability. Enabling controlled release.
Our proprietary soft gel technology is designed for lipophilic and poorly water-soluble APIs, enabling improved absorption and consistent exposure. In addition to solubilisation, our platform supports sustained and controlled release profiles, allowing precise modulation of pharmacokinetics.
Nasal Drug Delivery
Rapid, non-invasive. Engineered for CNS access.
Our nasal platform is optimised to minimise nasal mucosal irritation while enabling efficient systemic delivery and nose-to-brain transport. This approach supports rapid onset therapies and targeted CNS delivery by facilitating transport across the blood–brain barrier.
High-Volume Depot Injections
Long-acting therapy. Rapid administration.
Our depot injection technology enables controlled release over extended durations, while uniquely supporting high-volume delivery (3–5 mL in under one minute) via a handheld device. This allows efficient administration of high-dose therapies with improved patient convenience and adherence.